Date: 2014-05-27
Type of information: Distribution agreement
Compound: Pamorelin® LA (triptorelin)
Company: Orient EuroPharma (Singapour) Debiopharm (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation distribution
Action mechanism: Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl® /Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US.
Disease: locally advanced or metastatic, hormone-dependent prostate cancer.
Details: * On May 27, 2014, Orient EuroPharma, a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines, and Debiopharm, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs along with companion diagnostics, jointly announced the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia.The drug has been launched in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.
Financial terms:
Latest news:
